Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 15:04:47 05/06/2024 BST			5-day change	1st Jan Change
0.007 ^USD	+6.06%		-13.58%	-68.18%

02-22	Baudax Bio, Inc. Filed for Bankruptcy	CI
2023	Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Baudax Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

February 23, 2023 at 01:11 pm

Baudax Bio, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was USD 0.31 million compared to USD 0.4 million a year ago. Net loss was USD 9.25 million compared to net income of USD 29.43 million a year ago.

Basic loss per share from continuing operations was USD 12.33 compared to basic earnings per share from continuing operations of USD 486.26 a year ago. Diluted loss per share from continuing operations was USD 12.33 compared to diluted earnings per share from continuing operations of USD 437.19 a year ago.

Latest news about Baudax Bio, Inc.

Baudax Bio, Inc. Filed for Bankruptcy	02-22	CI
Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Baudax Bio, Inc.(OTCPK:BXRX) dropped from S&P TMI Index	11-20	CI
Baudax Bio, Inc.(OTCPK:BXRX) dropped from NASDAQ Composite Index	11-16	CI
Baudax Bio, Inc. to Initiate TI-168 Clinical Development	18/10/23	CI
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	06/10/23	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	06/10/23	MT
Baudax Bio Appoints Natalie McAndrew as Interim Finance Chief	06/10/23	MT
Baudax Bio, Inc. Announces Board Changes	06/10/23	CI
Baudax Bio, Inc. Announces Chief Financial Officer Changes	06/10/23	CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/09/23	MT
Top Premarket Decliners	29/09/23	MT
Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors	29/09/23	CI
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	28/09/23	MT
Sector Update: Health Care	28/09/23	MT
Top Midday Gainers	28/09/23	MT
Baudax Bio Shares Double After Orphan Drug Designation for TI-168	28/09/23	DJ
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	28/09/23	MT
Baudax Bio Files Registration Statement on Behalf of Selling Stockholder	22/09/23	MT
Baudax Bio, Inc. Enters into Amendment No. 7 to the Credit Agreement	05/09/23	CI
Baudax Bio, Inc. announced that it expects to receive $50 million in funding from Alumni Capital LP	22/08/23	CI
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/08/23	CI
Baudax Bio, Inc., Baudax Bio N.A. LLC, Baudax Bio Limited and TeraImmune, LLC enter Amendment No. 1 to Forbearance Agreement and Amendment No. 6 to Credit Agreement	31/07/23	CI
Baudax Bio, Inc. Appoints Yong Chan Kim as A Member of the Board	05/07/23	CI
Certain Common Stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2023.	30/06/23	CI

Chart Baudax Bio, Inc.

Duration

Period

More charts

Company Profile

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BAUDAX BIO, INC.	-68.18%	346K
MODERNA, INC.	+51.89%	55.7B
LONZA GROUP AG	+41.08%	39.91B
IQVIA HOLDINGS INC.	-5.92%	39.57B
CELLTRION, INC.	-5.56%	28.16B
ICON PUBLIC LIMITED COMPANY	+16.12%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-19.81%	18.94B
MEDPACE HOLDINGS, INC.	+31.85%	12.17B
UNITED THERAPEUTICS CORPORATION	+26.49%	12.12B
BIO-TECHNE CORPORATION	+1.35%	12.12B

Other Biotechnology & Medical Research

Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Baudax Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

Latest news about Baudax Bio, Inc.

Chart Baudax Bio, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research